Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of schizophrenia in adults.

After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as KarXT or Cobenfy. It comes without common side effects such as weight gain a

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely different way from existing medications for schizophrenia, which is building excitement and enthusiasm among doctors and patients alike.